Product Code: RP-ID-10079062 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10079062
Market Overview:
Global Oncology Drugs Industry Overview | By Product (Antimetabolite, Alkaloid drugs, Hormone, Targeted drug, Platinum-based drugs, other), and Application (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Other) - Global Market Opportunity and Current Growth Analysis 2019-2025
Global Oncology Drugs Industry was valued at USD 89.7 Billion in the year 2018. Global Oncology Drugs Industry is further estimated to grow at a CAGR of 6.6% from 2019 to reach USD 157.65 Million by the year 2025. Cancer Treatment Drugs are used to treat malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others.
Oncology Drugs is widely used For Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer and Other Cancer Treatment. The most proportion of Oncology Drugs used for Blood Cancer and the proportion in 2017 is 22.74%.
The structure of the global Oncology Drugs Industry is broke down utilizing Porter's Five Forces Model. As indicated by Porter's examination, the haggling intensity of purchasers is low due mind-boggling expense of medications, lesser information about the items/drugs. Notwithstanding, the haggling intensity of providers will in general moderate inferable from their lower focus and necessity of higher capital venture. Disease drugs are generally ensured with IPR rights therefore, prompts increment in the hindrances for new contestants.
global Oncology Drugs Industry by helpful modalities is segmented into chemotherapy, Targeted treatment, Immunotherapy, Hormonal treatment and others. Immunotherapy commands the worldwide market for malignancy medicates because of its high adequacy and less symptoms. Monoclonal antibodies, for example, trastuzumab, bevacizumab and rituximab are potential immunotherapeutic operators that have accomplished unselfish deals. The disease immunotherapy Industry is basically determined by immense research speculations from global organizations alongside research joint efforts for the advancement of malignant growth immunotherapeutics. In the course of recent years, directed malignant growth treatments have increased huge consideration because of their tumor cell explicit activity in shielding solid cells from the lethal impacts of Oncology Drugs.
Major market players in Oncology Drugs Industry are Roche, HENGRUI, AstraZeneca, QILU, Sanofi, HANSOH, LUYE, Novartis, GuiZhou YiBai, Lunan, Eli Lilly and Company and brief information of 9 more companies is provided in the report.
Oncology Drugs Industry Segmentation:
Oncology Drugs Industry Overview, By Product
ï¬Antimetabolite
ï¬Alkaloid drugs
ï¬Hormone
ï¬Targeted drug
ï¬Platinum-based drugs
ï¬Other
Oncology Drugs Industry Overview, By Application
ï¬Blood Cancer
ï¬Breast Cancer
ï¬Gastrointestinal Cancer
ï¬Prostate Cancer
ï¬Respiratory/Lung Cancer
ï¬Other
Oncology Drugs Industry Overview, By Region
North America
• USA
• Canada
Europe
• Germany
• U.K.
• France
• Italy
• Rest of Europe
APAC
• China
• India
• Japan
• Rest of Asia-Pacific
RoW
• Latin America
• Middle East & Africa
Related Reports
Proof of Quality & Reliability
